Skip to main content

Table 1 Study summaries in trials reporting relapse and disability progression

From: Relating relapse and T2 lesion changes to disability progression in multiple sclerosis: a systematic literature review and regression analysis

Trial

Follow-up (months)

Comparison

Patients analyzed

ARR experimental arm

ARR control arm

Relapse rate ratio

EDSS progression experimental arm

EDSS Progression control arm

Disability risk ratio

Comi G, et al., [17]

24

IFNB-1a 22 μg vs. Placebo

309

0.33

0.43

0.767

15.00

20.00

0.750

Hartung HP, et al. [24]

36

Mitoxantrone 12 mg vs. Placebo

124

0.35

1.02

0.343

8.00

22.00

0.364

Durelli L, et al. [18]

24

IFNB-1a 30 μg vs. IFNB-1b 250 μg

188

0.50

0.70

0.714

13.00

30.00

0.433

Rudick RA, et al. [38]

24

IFNB-1a plus Natalizumab vs. IFNB- 1a

1,171

0.34

0.75

0.453

23.00

29.00

0.793

Havrdova E, et al. [25]

24

IFNB-1a plus azathioprinethioprine vs. IFNB-1a

116

0.91

1.05

0.867

20.70

16.80

1.232

Havrdova E, et al. [25]

24

IFNB-1a plus azathioprine plus prednisone vs. IFNB-1a

120

0.73

1.05

0.695

17.50

16.80

1.042

Mikol DD, et al. [32]

22

IFNB-1a vs. Glatiramer acetate

764

0.29

0.30

0.967

8.70

11.70

0.744

Ravnborg M, et al. [37]

36

IFNB-1a plus Methylprednisolone vs. IFNB-1a

338

0.21

0.33

0.636

25.00

28.50

0.877

Sorensen P, et al. [39]

22

IFNB-1a plus Methylprednisolone vs. IFNB-1a

130

0.22

0.59

0.373

16.00

25.00

0.640

O’Connor P, et al. [34]

42

Glatiramer acetate vs. IFNB-1b 250 μg

1,158

0.34

0.36

0.944

20.50

22.30

0.919

O’Connor P, et al. [34]

42

Glatiramer acetate vs. IFNB-1b 500 μg

1,100

0.34

0.33

1.030

20.50

22.30

0.919

Gonsette RE, et al. [23]

24

IFNB-1b plus Inosine vs. IFNB-1b

157

0.50

0.38

1.316

17.78

18.18

0.978

Coles AJ, et al. [16]

36

Alemtuzumab vs. IFNB-1a

333

0.1

0.36

0.278

9.00

26.20

0.344

Kappos L, et al. [30]

24

Fingolimod 0.5 mg vs. Placebo

843

0.18

0.40

0.450

17.70

24.10

0.734

Kappos L, et al. [30]

24

Fingolimod 1.25 mg vs. Placebo

847

0.16

0.40

0.400

16.60

24.10

0.689

Polman CH, et al. [36]

24

Natalizumab vs. Placebo

942

0.23

0.73

0.315

17.00

29.00

0.586

Clanet M, et al. [14]

36

IFNB-1a 30 μg vs. IFNB-1a 60 μg

802

0.81

0.77

1.052

37.00

37.00

1.000

Ebers GC, et al. [9]

104

IFNB-1a 22 μg vs. Placebo

376

0.91

1.28

0.711

30.00

38.00

0.789

Ebers GC, et al. [9]

104

IFNB-1a 44 μg vs. Placebo

373

0.87

1.28

0.676

26.50

38.00

0.697

Johnson KP, et al. [27]

24

Glatiramer acetate vs. Placebo

251

0.59

0.84

0.702

21.60

24.60

0.878

Achiron A, et al. [11]

24

Immunoglobulin vs. Placebo

40

0.59

1.61

0.366

13.70

17.10

0.801

Baumhackl U, et al. [13]

24

Hydrolytic enzymes vs. Placebo

291

0.63

0.74

0.851

28.00

26.00

1.077

Fazekas F, et al. [20]

24

Immunoglobulin vs. Placebo

148

0.52

1.26

0.413

17.00

23.00

0.739

Millefiorini E, et al.[33]

24

Mitoxantrone vs. Placebo

51

0.445

1.31

0.340

7.00

37.00

0.189

Jacobs LD, et al. [26]

24

IFNB-1a vs. Placebo

172

0.61

0.90

0.678

21.10

33.30

0.633

Ebers GC, et al. [8]

36

IFNB-1b 1.6 MIU vs. Placebo

228

1.05

1.21

0.868

28.00

28.00

1.000

Ebers GC, et al. [8]

36

IFNB-1b 8 MIU vs. Placebo

227

0.84

1.21

0.694

20.00

28.00

0.714

van de Wyngaert FA, et al. [40]

36

Mitoxantrone vs. Methylprednisolone

28

0.26

1.00

0.260

21.00

21.00

1.000

Andersen O et al. [12]

36

IFNB-1a 22 μg vs. Placebo

364

0.25

0.27

0.926

41.00

38.00

1.079

Cohen JA, et al. [15]

24

IFNB-1a 60 μg vs. Placebo

379

0.20

0.30

0.667

28.50

33.70

0.846

Panitch H, et al. [35]

36

IFNB-1b 160 μg vs. Placebo

622

0.20

0.28

0.714

39.00

34.00

1.147

Panitch H, et al. [35]

36

IFNB-1b 250 μg vs. Placebo

625

0.16

0.28

0.571

32.00

34.00

0.941

Kappos L, et al. [28]

36

IFNB-1b vs. Placebo

718

0.44

0.64

0.688

38.90

49.70

0.783

Edan G, et al. [41]

36

Mitoxantrone 12 mg/m2 vs. IFNβ-1b 250 μg

109

0.39

0.71

0.549

9.10

25.90

0.351

Freedman MS, et al. [42]

24

MBP8298 vs. Placebo in DR2+ and/or DR4+ haplotypes

513

0.13

0.14

0.929

30.70

27.80

1.104

Freedman MS, et al. [42]

24

MBP8298 vs. Placebo in DR2- and/or DR4- haplotypes

99

0.08

0.20

0.400

28.30

35.80

0.791

Comi G, et al. [45]

24

Laquinimod 0.6 mg vs. Placebo

1,106

0.30

0.39

0.769

11.10

15.70

0.707

Cohen JA, et al. [43]

24

Alemtuzumab 12 mg vs. IFNβ-1a 44 μg

563

0.18

0.39

0.462

8.00

11.12

0.719

Coles AJ, et al. [44]

24

Alemtuzumab 12 mg vs. IFNβ-1a 44 μg

667

0.26

0.52

0.500

12.71

21.13

0.602

Fox RJ, et al. [46]

24

Dimethyl fumarate 240 mg BID vs. Placebo

480

0.22

0.40

0.550

13.00

17.00

0.765

Fox RJ, et al. [46]

24

Dimethyl fumarate 240 mg TID vs. Placebo

466

0.20

0.40

0.500

13.00

17.00

0.765

Fox RJ, et al. [46]

24

Glatiramer acetate vs. Placebo

471

0.29

0.40

0.725

16.00

17.00

0.941

  1. ARR, annualized relapse rate; BID, twice daily; EDSS, Expanded Disability Status Scale; IFNB, Interferon-beta; μg, microgram; mg, milligram; mg/m2, milligrams per square meter of body surface; MIU, million international units; TID, three times daily.